A Multicenter Observational Retrospective Study of Second-Line Treatment With Daratumumab-Bortezomib-Dexamethasone (DaraVd) in Multiple Myeloma (MM) Patients Refractory to Lenalidomide

被引：0
|
作者：
Rizzello, Ilaria [1 ]
Sacchetti, Ilaria [1 ]
Barbato, Simona [1 ]
Solli, Vincenza [1 ]
Stefanoni, Paola [2 ]
Cani, Lorenzo [3 ]
Pavan, Laura [4 ]
Quaresima, Micol [5 ]
Belotti, Angelo [6 ]
Sgherza, Nicola [7 ]
Gentile, Massimo [8 ]
Barila, Gregorio [9 ]
Patriarca, Francesca [10 ]
Celli, Melania [11 ]
Vincelli, Iolanda Donatella [12 ]
Mancuso, Katia [1 ]
Sartor, Chiara [1 ]
Pantani, Lucia [1 ]
Tacchetti, Paola [1 ]
Talarico, Marco [1 ]
Puppi, Michele [1 ]
Bigi, Flavia [1 ]
Cavo, Michele [1 ]
Zamagni, Elena [1 ]
机构：
[1] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy
[2] ASST Papa Giovanni XXIII, Dept Oncol & Hematol, Bergamo, Italy
[3] AOU Citta Salute & Sci Torino, Div Hematol, Turin, Italy
[4] AOU Padova, Ematol, Padua, Italy
[5] AUSL Reggio Emilia, Ematol, Reggio Emilia, Italy
[6] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy
[7] AOUC Policlin, Hematol, Bari, Italy
[8] AO Cosenza, Dept Oncohematol, Hematol Unit, Cosenza, Italy
[9] Osped San Bortolo, Ematol, Vicenza, Italy
[10] Azienda Sanit Univ Friuli Cent, Clin Ematol, Cosenza, Italy
[11] Osped Infermi Rimini, UO Ematol, Rimini, Italy
[12] GOM Bianchi Melacrino Morelli, UOC Ematol, Reggio Di Calabria, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-416
引用
收藏
页码：S275 / S275
页数：1
相关论文
共 50 条
  • [1] A NON-INTERVENTIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF SECOND-LINE TREATMENT WITH THE COMBINATION DARATUMUMAB - BORTEZOMIB - DEXAMETHASONE (DARAVD) IN MULTIPLE MYELOMA PATIENTS REFRACTORY TO LENALIDOMIDE
    Rizzello, I.
    Zamagni, E.
    Solli, V.
    Poletti, A.
    Tacchetti, P.
    Pantani, L.
    Mancuso, K.
    Rocchi, S.
    De Cicco, G.
    Fusco, A.
    Ursi, M.
    Barbato, S.
    Terragna, C.
    Martello, M.
    Testoni, N.
    Marzocchi, G.
    Cavo, M.
    HAEMATOLOGICA, 2021, 106 (10) : 167 - 168
  • [2] A REAL-LIFE STUDY OF DARATUMUMAB-BORTEZOMIB-DEXAMETHASONE (DVD) IN LENALIDOMIDE EXPOSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REPORT FROM THE MYELOMA TRIVENETO WORKING GROUP
    Barila, G.
    Quaglia, F. M.
    Furlan, A.
    Pescosta, N.
    Patriarca, F.
    Pascarella, A.
    De March, E.
    Lico, A.
    Sartori, R.
    De Sabbata, G.
    Marcon, C.
    Vedovato, S.
    Wieczoreck, M.
    Nappi, D.
    De Marchi, R.
    Gherlinzoni, F.
    Krampera, M.
    Semenzato, G.
    Zambello, R.
    HAEMATOLOGICA, 2021, 106 (10) : 60 - 60
  • [3] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [4] A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group
    Gregorio Barilà
    Francesca Maria Quaglia
    Anna Furlan
    Norbert Pescosta
    Angela Bonalumi
    Chiara Marcon
    Anna Pascarella
    Martina Tinelli
    Elena De March
    Albana Lico
    Roberto Sartori
    Cristina Clissa
    Giovanni De Sabbata
    Davide Nappi
    Marika Porrazzo
    Roberta De Marchi
    Laura Pavan
    Alberto Tosetto
    Filippo Gherlinzoni
    Mauro Krampera
    Renato Bassan
    Francesca Patriarca
    Gianpietro Semenzato
    Renato Zambello
    Annals of Hematology, 2024, 103 : 125 - 132
  • [5] A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group
    Barila, Gregorio
    Quaglia, Francesca Maria
    Furlan, Anna
    Pescosta, Norbert
    Bonalumi, Angela
    Marcon, Chiara
    Pascarella, Anna
    Tinelli, Martina
    De March, Elena
    Lico, Albana
    Sartori, Roberto
    Clissa, Cristina
    De Sabbata, Giovanni
    Nappi, Davide
    Porrazzo, Marika
    De Marchi, Roberta
    Pavan, Laura
    Tosetto, Alberto
    Gherlinzoni, Filippo
    Krampera, Mauro
    Bassan, Renato
    Patriarca, Francesca
    Semenzato, Gianpietro
    Zambello, Renato
    ANNALS OF HEMATOLOGY, 2024, 103 (01) : 125 - 132
  • [6] Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
    Sonneveld, Pieter
    Zweegman, Sonja
    Cavo, Michele
    Nasserinejad, Kazem
    Broijl, Annemiek
    Troia, Rosella
    Pour, Ludek
    Croockewit, Sandra
    Corradini, Paolo
    Patriarca, Francesca
    Wu, Kalung
    Droogendijk, Jolanda
    Bos, Gerard
    Hajek, Roman
    Teresa Petrucci, Maria
    Ypma, Paula
    Zojer, Nicholas
    Minnema, Monique C.
    Boccadoro, Mario
    HEMASPHERE, 2022, 6 (10): : E786
  • [7] Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
    Aceituno, Susana
    Gozalbo, Irmina
    Appierto, Marilena
    Lizan, Luis
    MEDWAVE, 2018, 18 (03):
  • [8] Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma
    Lund, Johan
    Gruber, Astrid
    Lauri, Birgitta
    Duru, Adil Doganay
    Blimark, Cecilie
    Swedin, Agneta
    Hansson, Markus
    Forsberg, Karin
    Ahlberg, Lucia
    Carlsson, Conny
    Waage, Anders
    Gimsing, Peter
    Vangsted, Annette Juul
    Frolund, Ulf
    Holmberg, Erik
    Gahrton, Gosta
    Alici, Evren
    Hardling, Mats
    Mellqvist, Ulf-Henrik
    Nahi, Hareth
    CANCER MEDICINE, 2018, 7 (06): : 2256 - 2268
  • [9] Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study
    Dimopoulos, Meletios Athanasios
    Beksac, Meral
    Benboubker, Lotfi
    Roddie, Huw
    Allietta, Nathalie
    Broer, Esther
    Couturier, Catherine
    Mazier, Marie-Andree
    Angermund, Ralf
    Facon, Thierry
    BLOOD, 2011, 118 (21) : 810 - 811
  • [10] EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    San-Miguel, J.
    Weisel, K.
    Cook, G.
    Leiba, M.
    Suzuki, K.
    Kumar, S.
    Cavo, M.
    Avet-Loiseau, H.
    Quach, H.
    Hungria, V.
    Lentzsch, S.
    Hajek, R.
    Sonneveld, P.
    Wu, K.
    Qin, X.
    Chiu, C.
    Soong, D.
    Qi, M.
    Schecter, J.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2017, 102 : 1 - 2
12345